+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group



Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group



Mayo Clinic Proceedings 91(9): 1189-1211



Thrombotic microangiopathies (TMAs) comprise a heterogeneous set of conditions linked by a common histopathologic finding of endothelial damage resulting in microvascular thromboses and potentially serious complications. The typical clinical presentation is microangiopathic hemolytic anemia accompanied by thrombocytopenia with varying degrees of organ ischemia. The differential diagnoses are generally broad, while the workup is frequently complex and can be confusing. This statement represents the joint recommendations from a multidisciplinary team of Mayo Clinic physicians specializing in the management of TMA. It comprises a series of evidence- and consensus-based clinical pathways developed to allow a uniform approach to the spectrum of care including when to suspect TMA, what differential diagnoses to consider, which diagnostic tests to order, and how to provide initial empiric therapy, as well as some guidance on subsequent management.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059131177

Download citation: RISBibTeXText

PMID: 27497856

DOI: 10.1016/j.mayocp.2016.05.015


Related references

Complement alternative pathway activation in the course of thrombotic microangiopathy associated with adult-onset Still's disease. Transfusion and Apheresis Science 49(3): 533-534, 2013

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 122(12): 2003-2007, 2013

Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet. Haematology 3(5): E237-E245, 2016

Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 24(5): 989-996, 2018

De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. American Journal of Kidney Diseases 41(2): 471-479, 2003

The arginine-nitric oxide pathway in thrombotic microangiopathy. Scandinavian Journal of Urology and Nephrology 31(5): 477-479, 1997

The arginine-nitric oxide pathway is activated in thrombotic microangiopathy. Journal of the American Society of Nephrology 6(3): 480, 1995

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrology Dialysis Transplantation 24(2): 682-685, 2009

Acute thrombotic thrombocytopenic purpura with hemolytic anemia; thrombotic microangiopathy; Moschcowitz disease. La Semaine des Hopitaux 33(38/6): 359-66/P, 1957

Complement activation in thrombotic microangiopathy. Hamostaseologie 33(2): 96, 2013

Complement-dependent, monoclonal gammapathy-associated thrombotic microangiopathy. Kidney International 92(2): 516, 2017

Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Advances 2(16): 2090-2094, 2018

Nephrological aspects of complement-mediated thrombotic microangiopathy. Terapevticheskii Arkhiv 89(6): 34-40, 2017

Complement, thrombotic microangiopathy and disseminated intravascular coagulation. Journal of Intensive Care 2(1): 65, 2014

Complement activation in diseases presenting with thrombotic microangiopathy. European Journal of Internal Medicine 24(6): 496-502, 2013